Myriad Genetics, Inc. (LON:0K3W)

Longboard Pharmaceuticals Revenue

Myriad Genetics had revenue of $195.90M USD in the quarter ending March 31, 2025, a decrease of -3.12%. This brings the company's revenue in the last twelve months to $831.30M, up 7.38% year-over-year. In the year 2024, Myriad Genetics had annual revenue of $837.60M with 11.21% growth.

• Revenue (ttm): $831.30M
• Revenue Growth: +7.38%
• P/S Ratio: 0.42
• Revenue / Employee: $307.89K
• Employees: 2,700
• Market Cap: 272.09M

Revenue Chart

* This company reports financials in USD.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	837.60M	84.40M	11.21%
Dec 31, 2023	753.20M	74.80M	11.03%
Dec 31, 2022	678.40M	-12.20M	-1.77%
Dec 31, 2021	690.60M	133.60M	23.99%
Dec 31, 2020	557.00M	-81.60M	-12.78%